Biotech bil­lion­aire spends $88M to re­or­ga­nize his long-suf­fer­ing bio­engi­neer­ing busi­ness­es, hands off CEO role

6 years ago
R&D

Chi­na green­lights home­grown pneu­mo­coc­cal, HPV vac­cines for the mar­ket — break­ing grips by Pfiz­er, Mer­ck

6 years ago
China
FDA+

‘No one ex­pects to get a knight­hood’: As­traZeneca’s Mene Pan­ga­los knight­ed for his lead­ing role in UK life ...

6 years ago
People

Decades old tu­ber­cu­lo­sis vac­cine di­rect­ly in­ject­ed in­to veins could tur­bocharge pro­tec­tion, mon­key study finds

6 years ago
R&D

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

6 years ago
Special
Pharma

Savara gets FDA break­through sta­tus de­spite large, late-stage fail­ure

6 years ago
R&D
FDA+

De­spite ques­tion­able PARP da­ta, FDA stamps quick OK on Lyn­parza as a front­line ther­a­py for pan­cre­at­ic can­cer

6 years ago
Pharma

Wave spot­lights ‘pos­i­tive’ da­ta on Hunt­ing­ton’s drug, but stock takes a beat­ing as Roche, Io­n­is ri­val stays in ...

6 years ago
R&D

Chi­nese court sen­tences Jiankui He to 3 years in jail — and con­firms birth of 3rd CRISPR ba­by

6 years ago
China
Cell/Gene Tx

An­tibi­otics apoc­a­lypse: Melin­ta files for bank­rupt­cy pro­tec­tion as a plague of woes af­flicts the field

6 years ago
R&D

Bank­ing on Shang­hai's biotech boom, this Eli Lil­ly-backed play­er grabs $100M to push next-gen I/O ther­a­pies

6 years ago
Financing
Startups

On a spree, Astel­las bags a next-gen, Park­er-backed CAR-T plat­form with $665M buy­out deal

6 years ago
R&D

Biotech takes a Christ­mas beat­ing af­ter safe­ty fears force re­searchers to halt all hep B stud­ies

6 years ago
R&D

Spec­trum shares crater as first round of piv­otal da­ta for their TKI falls short of pri­ma­ry end­point

6 years ago
R&D

The top 10 most pop­u­lar End­points News pieces of 2019 — go­ing vi­ral is a whole new game in bio­phar­ma now

6 years ago
R&D

FDA makes it of­fi­cial, once again re­ject­ing bat­tered Cor­re­vio’s heart drug

6 years ago
R&D

Sanofi's hur­ried, $2.5B pur­suit for Syn­thorx drove buy­out price high and left keen ri­val sore­ly dis­ap­point­ed

6 years ago
Deals

Gilead gets ball rolling on JAKs game in Japan

6 years ago
R&D

As Bris­tol-My­ers, Pfiz­er bat­tle copy­cat chal­lengers in court, FDA ap­proves gener­ics for block­buster Eliquis

6 years ago
FDA+

Al­ler­gan gets a win: FDA ap­proves ubro­gepant as cas­cade of treat­ments re­shape mi­graine field

6 years ago
R&D

In­tra-Cel­lu­lar's check­ered de­vel­op­men­tal path ends in schiz­o­phre­nia ap­proval, shares sky­rock­et

6 years ago
FDA+

Over a decade in­to the mile­stone boom, it's time to ask. Just how of­ten do they re­al­ly pay off?

6 years ago
Deals
In Focus

Pfiz­er inks a back-end­ed $250M deal for skin-tar­get­ed JAK, pays $25M to set up the next leg of their he­mo­phil­ia A R&D ...

6 years ago
News Briefing

J&J rounds out the year with twin buy­outs, gain­ing con­trol of de­liv­ery and sur­gi­cal ro­bot­ics tech

6 years ago
Deals
First page Previous page 867868869870871872873 Next page Last page
A service from the Financial Times